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Research Article
FAM83F regulates canonical Wnt signalling through an
interaction with CK1α
Karen Dunbar1 , Rebecca A Jones2 , Kevin Dingwell2, Thomas J Macartney1, James C Smith2 , Gopal P Sapkota1
The function of the FAM83F protein, like the functions of many
members of the FAM83 family, is poorly understood. Here, we
show that injection of Fam83f mRNA into Xenopus embryos
causes axis duplication, a phenotype indicative of enhanced Wnt
signalling. Consistent with this, overexpression of FAM83F acti-
vates Wnt signalling, whereas ablation of FAM83F from human
colorectal cancer (CRC) cells attenuates it. We demonstrate that
FAM83F is farnesylated and interacts and co-localises with CK1α
at the plasma membrane. This interaction with CK1α is essential
for FAM83F to activate Wnt signalling, and FAM83F mutants that
do not interact with CK1α fail to induce axis duplication in
Xenopus embryos and to activate Wnt signalling in cells. FAM83F
acts upstream of GSK-3β because the attenuation of Wnt sig-
nalling caused by loss of FAM83F can be rescued by GSK-3 inhi-
bition. Introduction of a farnesyl-deficient mutant of FAM83F in cells
through CRISPR/Cas9 genome editing redirects the FAM83F–CK1α
complex away from the plasma membrane and significantly atten-
uates Wnt signalling, indicating that FAM83F exerts its effects on Wnt
signalling at the plasma membrane.
DOI 10.26508/lsa.202000805 | Received 1 June 2020 | Revised 14 December
2020 | Accepted 15 December 2020 | Published online 24 December 2020
Introduction
FAM83F belongs to the FAM83 family of proteins, which is char-
acterised by a conserved N-terminal DUF1669 domain. We have
recently shown that the DUF1669 domain mediates interaction with
the α, δ, or ε isoforms of the CK1 family of Ser/Thr protein kinases
(1). The FAM83 proteins direct the CK1 isoforms with which they
interact to distinct subcellular compartments, thereby potentially
regulating their substrate pools (1). All FAM83 proteins interact with
CK1α, albeit with varying affinity, while FAM83A, B, E, and H also in-
teract with CK1δ and ε isoforms (1). CK1α, δ and ε isoforms have been
implicated in numerous cellular processes including Wnt signalling,
mitosis, circadian rhythm, and DNA damage responses (2, 3, 4, 5).
There is now increasing evidence that FAM83 proteins regulate
the diverse biological roles of CK1 isoforms. For example, FAM83G
(also known as PAWS1) regulates canonical Wnt signalling down-
stream of the β-catenin destruction complex through association
with CK1α (6). Interestingly, two mutations within the DUF1669
domain of the FAM83G gene that cause palmoplantar keratoderma
result in the loss of FAM83G-CK1α interaction and attenuation of
Wnt signalling (7). FAM83D directs CK1α to the mitotic spindle to
ensure proper spindle alignment and timely exit from mitosis (8),
and FAM83H mutations that cause amelogenesis imperfecta retain
interaction with CK1 isoforms but are mis-localised in cells (9, 10).
However, the biological and biochemical roles of FAM83F are poorly
understood. High levels of FAM83F protein have been linked to
oncogenesis in glioma (11), lung cancer (12), oesophageal cancer
(13), and thyroid cancer (14) yet the underlying mechanisms remain
unknown. Sequence alignment of the conserved DUF1669 domain
reveals that FAM83F most resembles FAM83G and is the only other
FAM83 protein to induce Wnt reporter activity in an overexpression
assay (Fig S1). We, therefore, sought to explore whether FAM83F is
also involved in regulating canonical Wnt signalling.
Wnt signalling plays important roles in embryogenesis and cell
proliferation as well as in stem cell and adult tissue homeostasis
(15). The key effector of the canonical Wnt signalling pathway is
β-catenin. Under basal conditions, most β-catenin protein is lo-
cated at the adherens junctions, whereas cytoplasmic β-catenin
levels are kept in check by the β-catenin destruction complex. The
destruction complex is composed principally of two scaffold pro-
teins, Axin and Adenomatous polyposis coli (Apc), and two protein
kinases, glycogen synthase kinase-3β (GSK-3β), and casein kinase
1α (CK1α). Phosphorylation of β-catenin at S45 by CK1α primes
β-catenin for GSK-3β–mediated sequential phosphorylation at T41,
S37, and S33, which allows the β-transducin repeat-containing
protein (β-Trcp) to ubiquitylate β-catenin and facilitate its deg-
radation through the proteasome (16). Upon binding Wnt ligands,
the Wnt receptor Frizzled and co-receptor LRP6 recruit Dishevelled
and the β-catenin destruction complex to the plasma membrane.
This complex, termed the Wnt signalosome, in turn becomes
internalised in multivesicular bodies, thus sparing the degradation
of cytoplasmic β-catenin (17). The resultant stabilised β-catenin then
translocates to the nucleus, where it binds to its co-transcriptional
factor, T-cell factor (TCF), and triggers the transcription of Wnt target
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genes, such as Axin2, C-myc, and Cyclin D1 (18). Aberrant Wnt sig-
nalling is a common feature in various cancers, particularly those of
gastrointestinal origin including a vast majority of colorectal cancers
(CRC) (19).
In this study we explore the role of FAM83F in driving Wnt sig-
nalling in Xenopus embryos and tissue culture cells, including CRC
cells.
Results
FAM83F induces axis duplication in Xenopus embryos through an
interaction with CK1α
The activation of the canonical Wnt signalling pathway by ectopic
expression of Wnt ligands and mediators in early Xenopus embryos
causes axis duplication (20). Previously, we showed that injection of
Xenopus embryos with FAM83G mRNA into a ventral blastomere at
the four-cell stage induced secondary axis formation (6). Ectopi-
cally expressing mRNA in early Xenopus embryos is thus an efficient
method for screening potential regulators of canonical Wnt sig-
nalling. Upon injection of axis-inducing mRNA, four possible axial
phenotypes can result, including complete secondary axes, partial
secondary axes, dorsalised embryos, and those resembling wild-
type (Fig 1A). To test the impact of FAM83F on Xenopus embryos, 500
pg of mRNA encoding HA-tagged zebrafish fam83fa, which closely
resembles FAM83F in human and other species and was the only
construct available at the time, was injected into a single ventral
blastomere at the four-cell stage. Embryos were maintained until
approximately stage 35, at which point we counted the embryos
displaying each class of axial phenotype. HA-fam83fa induced
secondary axes in >60% of the Xenopus embryos (Fig 1B–D).
FAM83F interacts selectively with CK1α through its conserved
DUF1669 domain and mutating the phenylalanine residues from a
conserved F-X-X-X-F motif to alanine abolishes this interaction (1).
In zebrafish Fam83fa, these two phenylalanine residues map at
amino acid positions 275 and 279. Mutation of either F275 or F279 to
an alanine prevented the induction of a secondary axis (Fig 1B and
C), as did the double mutant, Fam83faF275A/F279A, despite all proteins
being expressed, as shown by Western blot (Fig 1D). This indi-
cates that Fam83fa-CK1α binding is required for Fam83fa to
induce axis duplication in Xenopus embryos. When we tested
Fam83fa fragments with deletions at the C terminus for their
ability to induce axis duplication, both full-length fam83famRNA
(HA-fam83fa1-555aa) and the DUF1669 domain fragment (HA-
fam83fa1-300aa) induced secondary axes robustly (Fig S2A–C).
Interestingly, the C-terminal deletions HA-fam83fa1-500aa, HA-
fam83fa1-400aa, and HA-fam83fa1-356aa induced secondary axes
poorly, indicating that loss of the C-terminal portion of the
protein affects Fam83fa structure or function.
Human FAM83F contains a protein prenylation motif, a con-
served CAAX box sequence at the C terminus in which the cysteine
residue is modified through an addition of either a geranylgeranyl
or a farnesyl moiety (21). When FAM83F that has been overex-
pressed in HEK-293 cells was isolated, cleaved with trypsin and
subjected to mass-spectrometry, we identified tryptic peptides
found to be farnesylated at Cys497 (Fig S3A–C). Farnesylation, a
posttranslational modification, involves the addition of a 15-carbon
farnesyl group to a C-terminal cysteine residue by farnesyl-
transferase; this plays a role in the regulation of protein-membrane
interactions and in signal transduction circuits (22). Zebrafish
Fam83fa, which possesses the CIQS sequence at its C terminus, is
also predicted to be farnesylated (23). Mutation in the human
protein of the CAAX-box invariant cysteine to an alanine, creating
FAM83FC497A, prevents farnesylation but injection of mRNA encoding
this mutated protein induced secondary axis formation in Xenopus
embryos in a similar manner to that of wild-type FAM83F (Fig S2D).
This indicates that farnesylation of the C terminus of FAM83F is not
required for its ability to activate canonical Wnt signalling in the
Xenopus assays.
FAM83F-CK1α interaction is required for FAM83F membrane
localisation and canonical Wnt signalling effects
Initial investigations of FAM83F biology were performed in the U2OS
Flp-In T-Rex (Flp/Trx) cell line, which allows doxycycline inducible
gene expression of stably integrated proteins of interest. Stable cell
lines were generated to express GFP only, GFP-FAM83A, GFP-
FAM83F, GFP-FAM83FC497A, GFP-FAM83FD250A, and GFP-FAM83FF284A/
F288A (Fig 2A). In addition to the previously described conserved F-X-
X-X-F motif, which is required for the FAM83-CK1 interactions, a
separate conserved residue that maps to an aspartic acid at 250 in
FAM83F was identified which when mutated to an alanine can also
disrupt FAM83-CK1 interactions (1) (Fig 2A). Immunoprecipitation of
GFP confirmed that GFP-FAM83F interacts with CK1α but no inter-
action was detected with GFP only or with GFP-FAM83A (Fig 2B). GFP-
FAM83FF284A/F288A does not interact with CK1α, while the interaction
between GFP-FAM83FD250A and CK1α is severely reduced compared
with wild type GFP-FAM83F (Fig 2B). The farnesyl-deficient mutant,
GFP-FAM83FC497A, still maintains an interaction with CK1α (Fig 2B).
Fluorescencemicroscopy shows that GFP-FAM83F is expressed at
both the plasma membrane and nucleus in U2OS Flp/Trx cells (Fig
2C). The farnesyl-deficient mutant GFP-FAM83FC497A was detectable
only in the nucleus, suggesting that farnesylation of FAM83F directs
its localisation to the plasma membrane. Interestingly, the two
CK1α-binding deficient mutants, GFP-FAM83FD250A and GFP-
FAM83FF284A/F288A, exhibited cytoplasmic and peri-nuclear local-
isation away from the plasma membrane and the nucleus. This
suggests that the membrane and nuclear localisation of FAM83F is
facilitated by its association with CK1α. Co-staining with an anti-
CK1α antibody revealed overlapping localisation with GFP-FAM83F
and GFP-FAM83FC497A, but not with GFP-FAM83FD250A and GFP-
FAM83FF284A/F288A (Fig 2C).
Canonical Wnt signalling activity can be measured using a dual
luciferase reporter assay in which cells are transfected with a
plasmid containing either wild-type TCF, a co-transcriptional ac-
tivator of β-catenin, binding sites (TOPflash) or mutant TCF-binding
sites (FOPflash) upstream of a luciferase reporter (24). An increase
in “free” β-catenin protein, following activation of Wnt signalling,
interacts with the TCF-binding sites, thereby inducing luciferase
expression and hence activity. Overexpression of GFP-FAM83F and
GFP-FAM83FC497A significantly increased luciferase reporter activity
in cells treated with control L-conditioned medium compared with
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Figure 1. Fam83f induces axis duplication in Xenopus embryos through an interaction with casein kinase 1α (CK1α).
(A) Bright-field microscopy images of Xenopus embryo axis duplication phenotypes; wild-type, dorsalised, partial secondary axis and complete secondary
axis. (B) Cartoon of Fam83fa protein illustrating the location of the CK1 binding and farnesylation motifs and cartoons of the point mutants expressed in (C, D).
(C) Percentage of Xenopus embryos showing phenotypes depicted in (A) following injection with HA-tagged zebrafish fam83fa, fam83faF275A, fam83faF279A, or
fam83faF275A/F279A mRNA. Data represent three independent experiments with total numbers of Xenopus embryos denoted above the graph. Bar graph
representing mean + SD. Statistical significance determined by two-way ANOVA with Tukey’s post hoc test to compare the percentage of embryos displaying a
wild-type phenotype. ****P ≤ 0.0001. (D) Protein extracts from Xenopus embryos following injection with HA tagged zebrafish fam83fa, fam83faF275A,
fam83faF279A, or fam83faF275A/F279A mRNA were resolved by SDS–PAGE and subjected to Western blotting with indicated antibodies.
Source data are available for this figure.
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GFP controls (Fig 2D). In contrast, overexpression of the CK1α-binding
deficient mutants GFP-FAM83FD250A and GFP-FAM83FF284A/F288A did
not increase luciferase activity under these conditions. Following
addition of Wnt3A-conditioned medium, GFP-FAM83F and GFP-
FAM83FC497A cell lines had significantly increased luciferase ac-
tivity when compared with Wnt3A-treated GFP controls (Fig 2D).
Wnt3A-induced luciferase reporter activity in cells expressing the
CK1α-binding deficient mutants GFP-FAM83FD250A and GFP-
FAM83FF284A/F288A was substantially lower than in cells expressing
GFP-FAM83F and GFP-FAM83FC497A (Fig 2D). This suggests that
FAM83F-induced Wnt reporter activity is mediated through its
association with CK1α. Expression of GFP tagged FAM83F proteins
do not appear to affect the overall nuclear translocation of en-
dogenous β-catenin basally or following Wnt3A stimulus, as ob-
served by immunofluorescence and in cytoplasmic/nuclear
fractions (Fig S4A and B). However, expression of GFP-FAM83F and
GFP-FAM83FC497A increases cytoplasmic β-catenin levels basally
compared with cells expressing GFP only or GFP-FAM83FF284A/F288A,
as demonstrated by subcellular fractionation (Fig S5). This in-
crease in “free” β-catenin potentially explains the increased TCF-
luciferase activity detected upon expression of GFP-FAM83F and
GFP-FAM83FC497A as the dual-luciferase assay only requires β--
catenin to bind to the artificial TCF promoter to induce luciferase
activity.
Endogenous FAM83F localises to the plasma membrane and
interacts with CK1α
To facilitate the study of endogenous FAM83F protein we screened
multiple tissues and cell lines to identify cell lines with detectable
levels of endogenous FAM83F protein. Tissue-specific expression of
FAM83F from mouse tissue extracts revealed that FAM83F protein
was detected in spleen, lung, and gastrointestinal tissues, with the
highest levels of FAM83F protein detected in the stomach, small
intestine, large intestine, and intestinal crypts (Fig 3A). Similar
assessment of a panel of routinely studied cell lines showed that
FAM83F protein was detected in extracts from the mammary ad-
enocarcinoma cell line MDA-MB-468, and the colorectal cancer cell
line HCT116, but was undetectable in many other cell lines (Fig S6A
and B). Separately, we detected FAM83F protein in extracts from
HaCaT keratinocytes as well as DLD-1 colorectal cells (Fig 3A and B).
Based on the abundance of FAM83F protein observed in gastro-
intestinal tissue extracts and colorectal cells, we proceeded with
two colorectal cancer cell lines, HCT116 and DLD-1, for further
investigation into the role of endogenous FAM83F in canonical Wnt
signalling. By using CRISPR/Cas9 technology, we generated FAM83F
knockout (FAM83F−/−) HCT116 (clones 1 and 2) and DLD-1 cells and also
knocked in a GFP tag N-terminal to the FAM83F gene homozygously in
both cell lines (HCT116 GFP/GFPFAM83F and DLD-1 GFP/GFPFAM83F) (Fig 3B).
Both knockouts and GFP-knockins were verified by DNA sequencing and
Western blotting (Figs 3B and S7A and B).
GFP-FAM83F immunoprecipitates (IPs) from HCT116 GFP/GFPFAM83F
andDLD-1 GFP/GFPFAM83F cell extracts but not fromwild-type cells co-
precipitated endogenous CK1α, but not CK1δ or CK1ε (Fig 3C). Similarly,
endogenous CK1α IPs co-precipitated FAM83F from wild-type HCT116
and DLD-1 cell extracts but not from HCT116 FAM83F−/− (cl.1) and DLD-
1 FAM83F−/− cell extracts (Fig 3D). The interaction between CK1α and
FAM83G was unaffected by FAM83F knockout because CK1α IPs co-
precipitated FAM83G from all cell extracts (Fig 3D). Endogenously
driven GFP-FAM83F in HCT116 GFP/GFPFAM83F knock-in cells localised
predominately to the plasma membrane, as revealed by anti-GFP
immunofluorescence (Fig 3E). Under these conditions, endoge-
nous CK1α immunostaining exhibited a diffuse pan-cellular
staining, which limited the detection of plasma membrane-
specific co-localisation with GFP-FAM83F. Immunofluorescence
using a FAM83F antibody in HCT116 wild-type cells confirmed the
plasma membrane localisation of endogenous FAM83F, which co-
localised with β-catenin, a marker of the adherens junctions (Fig
3F). The specificity of anti-FAM83F staining was demonstrated using
HaCaT wild-type and FAM83F−/− cell lines (Fig S8).
Knockout of FAM83F reduces canonical Wnt signalling in
colorectal cancer cells
Constitutively active Wnt signalling is a hallmark of many colorectal
cancers (CRCs) (19). Mutations in the Apc gene, which encodes a
central component of the β-catenin destruction complex and fa-
cilitates the destruction of free cytoplasmic β-catenin, are among
the most common in CRCs (25). DLD-1 cells express Apc truncated at
residue 1417, whilst HCT116 cells have a heterozygous mutation of
β-catenin at S45, which prevents β-catenin from being phos-
phorylated and then ubiquitinated and degraded (26, 27). Thus,
constitutive activation of Wnt signalling in HCT116 and DLD-1 cells
occurs through perturbations at different stages of the pathway,
and the responses to Wnt3A-ligand stimulation are also likely to
differ. Canonical Wnt signalling activity can be measured by the
transcript expression of Wnt target genes such as Axin2 (18) as
demonstrated by the >2-fold increase in Axin2 mRNA expression
following the addition of Wnt3A-CM to wild-type HCT116 cells (Fig
4A). In both HCT116 FAM83F−/− clones, the Wnt3A-induced increase
in Axin2mRNA abundance was significantly reduced compared with
wild-type HCT116 cells. Neither wild-type DLD-1 cells nor DLD-1
FAM83F−/− cells were responsive to treatment with Wnt3A-CM,
but DLD-1 FAM83F−/− cells had a slight but significant reduction
in basal Axin2 mRNA abundance. In addition to the two colorectal
cancer cell lines, we generated a FAM83F knockout in the osteo-
sarcoma cell line U2OS (Fig S9A). Endogenous FAM83F protein
abundance is low in U2OS cells, with detection only possible after
immunoprecipitation with an anti-FAM83F antibody. Canonical Wnt
activity was determined using the dual luciferase assay (Fig S9B)
and the endogenous Wnt target gene Axin2 (Fig S9C). U2OS wild-
type and U2OS FAM83F−/− cells respond to Wnt3A stimulus with
increased luciferase activity and Axin2 mRNA abundance, respec-
tively, but the extent of both responses was significantly reduced in
U2OS FAM83F−/− cells compared with U2OS wild-type cells (Fig S9B
and C).
We next sought to determine whether the FAM83F-CK1α inter-
action is affected by Wnt3A stimulation. CK1α IPs co-precipitated
endogenous FAM83F from wild-type HCT116 and DLD-1 cell extracts
but not from HCT116-FAM83F−/− (cl.1) and DLD-1-FAM83F−/− cell
extracts regardless of stimulation with L-CM or Wnt3A-CM for 6 h
(Fig 4B). We also analysed the components of the canonical Wnt3A
signalling pathway in these cells upon stimulation with Wnt3A-CM
(Fig 4C). A slight reduction in phospho-β-catenin (S45) was detected
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Figure 2. FAM83F-casein kinase 1α (CK1α) interaction is required for membrane localisation and canonical Wnt signalling effects.
(A) Cartoon of FAM83F protein illustrating the location of the CK1 binding and farnesylation motifs. Cartoons of the GFP-tagged FAM83F point mutants expressed in (B, C,
D) are also indicated. (B) Lysates from U2OS Flp/Trx cells expressing GFP, GFP-FAM83A, GFP-FAM83F, GFP-FAM83FC497A, GFP-FAM83FD250A, or GFP-FAM83FF284A/F288A were
subjected to immunoprecipitation with GFP trap beads. Input lysates and GFP IPs were resolved by SDS–PAGE and subjected to Western blotting with the indicated
antibodies. (C) Representative wide-field immunofluorescence microscopy images of U2OS Flp/Trx cells expressing GFP-FAM83F, GFP-FAM83FC497A, GFP-FAM83FD250A, or
GFP-FAM83FF284A/F288A, labelled with antibodies recognising GFP (far left panels, green), CK1α (second row of panels from left, magenta), and DAPI (third row of panels from
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in wild-type and FAM83F−/− HCT116 cells following addition of
Wnt3A-CM compared with L-CM controls, indicating activation of the
signalling pathway. However, the absence of phosphorylation of
LRP6 and increase in active β-catenin following Wnt3A stimulus is
surprising and may reflect the transient nature of phosphorylation
within signalling pathways, or a poor response to Wnt3A stimulus
due to constitutively active Wnt signalling in these cell lines. The
levels of phospho-LRP6 (S1490), total LRP6, phospho-β-catenin
(S33/S37/T41), active β-catenin, and total β-catenin were similar in
HCT116 wild-type, HCT116 FAM83F−/− (cl.1) and HCT116 FAM83F−/−
(cl.2) cells, regardless of Wnt3A stimulation (Fig 4C). Although there
was a slight increase in LRP6 levels in FAM83F−/− DLD-1 cells relative
to wild-type DLD-1 cells, no consistent changes in the abundance of
any other Wnt signalling pathway proteins or phospho-proteins
was evident between wild-type and FAM83F knockout DLD-1 cells,
regardless of Wnt3A stimulation.
FAM83F acts upstream of GSK-3β and the loss of FAM83F protein
reduces CK1α protein abundance at the plasma membrane
We sought to investigate where within the canonical Wnt/β-catenin
signalling pathway FAM83F was acting. If the inhibition of Wnt
signalling upon FAM83F loss can be restored by GSK-3 inhibitors,
which prevent the phosphorylation and subsequent ubiquitin-
mediated proteasomal degradation of β-catenin, this would im-
ply that FAM83F acts upstream of GSK-3β. As previously noted,
Wnt3A-induced Axin2 mRNA abundance was lower in HCT116
FAM83F−/− cells than in wild-type HCT116 cells (Fig 4A). However,
treatment of wild-type HCT116 and HCT116 FAM83F−/− cells with 0.5
μM CHIR99021, a selective GSK-3 inhibitor, enhanced Axin2 mRNA
abundance to a similar extent in both cell lines regardless of Wnt3A
stimulation (Fig 5A). In a similar assay, when U2OS wild-type and
U2OS FAM83F−/− cells were treated with 0.5 μM of CHIR99021, Axin2
mRNA abundance increased to a similar extent in both cell lines
regardless of Wnt3A stimulation (Fig S9C). These observations in-
dicate that FAM83F acts to modulate Wnt signalling upstream of
GSK-3β.
Given the plasma membrane localisation of FAM83F, as detected
by immunofluorescence (Figs 2C and 3E and F), we hypothesised
that FAM83F may influence canonical Wnt signalling at the mem-
brane. Wild-type HCT116, HCT116 FAM83F−/− (cl.1), and HCT116
FAM83F−/− (cl.2) cells were separated into cytoplasmic, nuclear and
membrane fractions (Fig 5B). In wild-type HCT116 cells, FAM83F was
detected predominately in the membrane fraction with a small
proportion in the nuclear fraction, whereas CK1αwas detected in all
three fractions: cytoplasmic, nuclear, and membrane (Fig 5B). In-
terestingly, CK1α protein abundance in the membrane fraction was
significantly reduced in both HCT116 FAM83F−/− (cl.1) and HCT116
FAM83F−/− (cl.2) cells compared with HCT116 wild-type cells (Fig 5C).
A similar result was observed using DLD-1 FAM83F−/− and DLD-1
wild-type cells (Fig 5D and E). These results suggest that FAM83F
directs CK1α to the plasma membrane.
Membranous localisation of FAM83F is required for FAM83F’s role
in canonical Wnt signalling
To investigate the importance of membrane bound FAM83F in
canonical Wnt signalling under physiological conditions, we sought
to knock-in a point mutation into the farnesylation motif of FAM83F,
C497A, which should prevent membrane anchorage of FAM83F,
using CRISPR/Cas9 genome editing (Fig 6A). We isolated three
clones, HCT116 FAM83FC497A (clones 1–3) which were confirmed by
genomic sequencing as homozygous (clones 1 & 3) and hetero-
zygous (clone 2; the second allele had additional random insertions
thereby also predictive of disrupting FAM83F membrane local-
isation) for the FAM83FC497A knock-in (Fig S10A and B). Separation of
HCT116 wild-type and FAM83FC497A cell extracts into cytoplasmic,
nuclear, and membrane fractions show a significant reduction in
FAM83F and CK1α protein in the membrane fractions in all HCT116
FAM83FC497A clones compared with wild-type cells (Fig 6B and C).
CK1α IPs fromHCT116 wild-type and HCT116 FAM83FC497A cell extracts
co-precipitated FAM83F but not from HCT116 FAM83F−/− cells (Fig
6D), confirming that farnesylation of FAM83F does not affect CK1α
binding. The role of FAM83F farnesylation in Wnt signalling was
determined by evaluating Axin2 mRNA expression in HCT116 wild-
type and FAM83FC497A clones following treatment with L-CM or
Wnt3A-CM for 6 h (Fig 6E). HCT116 FAM83FC497A clone 1 has signifi-
cantly reduced Axin2 transcript levels following Wnt3A stimulus
compared to wild-type cells, but no significant changes were ob-
served following L-CM treatment. HCT116 FAM83FC497A clones 2 and 3
have significantly reduced Axin2 transcript levels compared to wild-
type cells following both L-CM and Wnt3A-CM treatments. These
results indicate that farnesylation of FAM83F is required for ca-
nonical Wnt signalling in HCT116 cells.
Interestingly, the Wnt signalling deficit observed in all endog-
enous FAM83FC497A clones is in stark contrast to the induction of
Wnt signalling following overexpression of GFP-FAM83FC497A (Fig
2D). The overexpression of FAM83F proteins has been shown to alter
the localisation of CK1α with GFP-FAM83FC497A increasing nuclear
CK1α staining (Fig 2C). This re-direction of CK1α by GFP-FAM83FC497A
reduces cytoplasmic CK1α levels (Fig S11A). In turn, cells over-
expressing GFP-FAM83FC497A have significantly reduced levels of
phosphorylated β-catenin at serine 45, which requires CK1α and
triggers β-catenin ubiquitylation and degradation (Fig S11B and C).
Therefore, it is not unexpected that cells overexpressing GFP-
FAM83FC497A would be predicted to have increased “free”
left, blue). Overlay of GFP, CK1α, and DAPI images as a merge is shown on the right. Immunofluorescence images captured with a 60× objective. Scale bar represents 10
μm. (D) Relative luciferase activity in U2OS Flp/Trx cells expressing GFP, GFP-FAM83F, GFP-FAM83FC497A, GFP-FAM83FD250A, or GFP-FAM83FF284A/F288A treated with either L- or
Wnt3A-conditioned medium for 6 h. Luciferase activity is presented as TOPflash luciferase normalised to FOPflash luciferase and Renilla expression, the transfection
control plasmid. Data presented as scatter graph illustrating individual data points with an overlay of the mean ± SD. Expression of GFP, GFP-FAM83A, GFP-FAM83F, GFP-
FAM83FC497A, GFP-FAM83FD250A, and GFP-FAM83FF284A/F288A in U2OS Flp/Trx cells was induced by a treatment with 20 ng/ml doxycycline for 24 h. Statistical analysis of (C) was
completed using a Student’s unpaired t test and comparing cell lines as denoted on graph. Statistically significant P-values are denoted by asterisks (**** < 0.0001, *** <
0.001, ** < 0.01, * < 0.05).
Source data are available for this figure.
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Figure 3. Endogenous FAM83F localises to the plasma membrane and interacts with casein kinase 1α (CK1α).
(A) Extractions from mouse tissues: brain, heart, lung, liver, stomach, small intestine, large intestine, kidney, spleen, and intestinal crypts, plus HaCaT wild-type cells
were resolved by SDS–PAGE and subjected to Western blotting with indicated antibodies. (B) HCT116 wild-type, HCT116 FAM83F−/− (cl.1), HCT116 FAM83F−/− (cl.2), HCT116 GFP/
GFPFAM83F, DLD-1 wild-type, DLD-1 FAM83F−/−, and DLD1 GFP/GFPFAM83F cell extracts were resolved by SDS–PAGE and subjected to Western blotting with indicated
antibodies. (C) HCT116 wild-type, HCT116 GFP/GFPFAM83F, DLD-1 wild-type, and DLD-1 GFP/GFPFAM83F cell extracts were subjected to immunoprecipitation with GFP trap
beads. Input lysates and GFP IPs were resolved by SDS–PAGE and subjected to Western blotting with indicated antibodies. (D) HCT116 wild-type, HCT116 FAM83F−/− (cl.1),
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cytoplasmic β-catenin (Fig S5) and as such an increase in Wnt
signalling (Fig 2D). These conflicting results highlight the caveats
associated with evaluating cell signalling in overexpressionmodels.
At an endogenous level, we show that absence of farnesylated
FAM83F reduces membranous CK1α protein abundance and Wnt
signalling output, indicating that membrane bound FAM83F is re-
quired for both membrane localisation of CK1α and mediating
canonical Wnt signalling.
Discussion
Little is known about the function of FAM83F and in most tissues
and cell lines, except for the gastrointestinal tissues and colorectal
cancer cell lines, FAM83F protein levels are undetectable. Inter-
estingly, gastrointestinal tissues and colorectal cancer cells are
reliant on canonical Wnt signalling for homeostasis and mainte-
nance. In this study, we show that FAM83F mediates the canonical
Wnt/β-catenin signalling pathway both in developing Xenopus
embryos and in human cancer cells. We show that FAM83F is
localised at the plasma membrane through farnesylation and di-
rects CK1α to the plasma membrane. The FAM83F-CK1α complex
appears to act upstream of GSK-3β, and we show that the inter-
action between FAM83F and CK1α and their membrane localisation
is essential for driving Wnt signalling.
CK1 isoforms have been implicated in both positive and negative
regulation of Wnt/β-catenin signalling (3). This suggests that the
activity of CK1 isoforms is tightly regulated in a spatiotemporal
manner. As key regulators of the CK1 isoforms, it is highly likely that
the FAM83 proteins play a role. Any perturbation of the homeostatic
balance of endogenous CK1 pools in cells, caused, for example, by
overexpression of interacting proteins, is thus likely to disrupt
coordinated roles of CK1 isoforms in Wnt signalling. This explains
the apparent contradictory observations we made when over-
expressing FAM83FC497A in Xenopus embryos and in cells caused an
increase in canonical Wnt signalling, whereas the endogenous
knock-in of FAM83FC497A mutant attenuated Wnt signalling.
Expressing high levels of FAM83FC497A protein, which redirects much
of the endogenous CK1α protein to the nucleus, reduces the cy-
toplasmic pool of CK1α, thus removing inhibitory CK1α from the
β-catenin destruction complex and thereby activating the ca-
nonical Wnt signalling pathway.
We have shown that FAM83F and FAM83G/PAWS1 both activate
Wnt signalling, but FAM83F acts upstream of GSK-3β, whereas
FAM83G/PAWS1 acts downstream (6). The specific CK1α substrates
within the canonical Wnt signalling pathway which mediate the
effects of both FAM83F and FAM83G/PAWS1 are unknown.
Phosphorylation of β-catenin by CK1α at Ser45 is the most
established regulatory role of CK1α within the Wnt pathway and is
critical for priming subsequent GSK-3 phosphorylation, ubiq-
uitination, and degradation of β-catenin and thus inhibition of Wnt
signalling (28). P120-catenin is one of the few reported Wnt-
dependent CK1α substrates located at the plasma membrane.
The sequential phosphorylation of P120-catenin, at the adherens
junctions by CK1ε and CK1α is required for the internalisation of the
Wnt signalosome (17). The contradictory nature of the roles of CK1
isoforms in Wnt signalling can be demonstrated by the CK1δ/ε
isoforms which have been reported to phosphorylate multiple
proteins within the Wnt signalling pathway including Dishevelled
(29) and a co-transcriptional regulator, lymphoid enhanced binding
factor 1 (Lef-1) (30). Interestingly, phosphorylation of Dishevelled at
the membrane following Wnt stimulation promotes signalling,
whereas phosphorylation of Lef-1 in the nucleus is inhibitory; thus,
the same kinase can have opposing actions depending on sub-
cellular localisation. It will be interesting to determine whether and
how different FAM83 proteins coordinate the phosphorylation of
these and other CK1 substrates to fine tune Wnt signalling.
FAM83F has been implicated in oncogenesis in several cancers
(12, 14, 31), and increased abundance of FAM83F protein is also
associated with a more aggressive phenotype and poor prognosis
in oesophageal carcinoma (32). However, amechanistic explanation
for these oncogenic effects has not been forthcoming. We show
here that overexpression of FAM83F protein in cells increases both
basal and ligand-dependent canonical Wnt signalling which may
explain the reported increase in cell proliferation. FAM83F has also
been implicated in the stabilisation of p53 protein, a crucial tumour
suppressor, by decreasing p53 ubiquitination and degradation (33).
This stabilisation is also apparent with mutant p53 protein, thus
FAM83F may have a tumour suppressor or an oncogenic role
depending on the p53 mutational status of the cell (33). Interest-
ingly, CK1α has also been reported to influence p53 stabilisation
through binding to the E3 ligases MDM2 (34) and MDMX (35) which
inhibit p53 activity through ubiquitination and direct binding, re-
spectively. Therefore, these reported p53 effects may potentially be
another function of the FAM83F-CK1α complex. We propose that
FAM83F’s biological role is to mediate the localisation of a pro-
portion of CK1α and, thus, to facilitate phosphorylation of a subset
of CK1α substrates. Therefore, FAM83F may have effects in multiple
signalling pathways, beyond Wnt signalling and p53 activity,
through determining CK1α localisation and its substrates. Although
targeting CK1α therapeutically would have multiple unwanted
consequences, the potential to inhibit specific pools of CK1α and
potentially specific substrates through inhibition of the
FAM83F-CK1α complex couldmake FAM83F an attractive therapeutic
target in cancer.
DLD-1 wild-type, and DLD-1 FAM83F−/− cell extracts were subjected to immunoprecipitation with anti-CK1α antibody. Input lysates and CK1α IPs were resolved by
SDS–PAGE and subjected to Western blotting with indicated antibodies. (E) Representative wide-field immunofluorescence microscopy images of HCT116 GFP/GFPFAM83F
cells, labelled with antibodies recognising GFP (far left panels, green), CK1α (second row of panels from left, magenta), and DAPI (third row of panels from left, blue).
Overlay of GFP, CK1α, and DAPI images as a merge is shown on the right. Immunofluorescence images captured with a 60× objective. (F) Representative wide-field
immunofluorescence microscopy images of HCT116 wild-type cells, labelled with antibodies recognising FAM83F (far left panels, green), β-catenin (second row of panels
from left, magenta), and DAPI (third row of panels from left, blue). Overlay of FAM83F, β-catenin, and DAPI images as a merge is shown on the right. Immunofluorescence
images captured with a 100× objective. Scale bar represents 10 μm.
Source data are available for this figure.
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Figure 4. Knockout of FAM83F reduces canonical Wnt signalling in colorectal cancer cells.
(A) qRT-PCR was performed using cDNA from HCT116 wild-type, HCT116 FAM83F−/− (cl.1), HCT116 FAM83F−/− (cl.2), DLD-1 wild-type and DLD-1 FAM83F−/− cells following
treatment with L-CM orWnt3A-CM for 6 h, and primers for Axin2 and GAPDH genes. Axin2mRNA expression was normalised to GAPDHmRNA expression and represented as
fold change compared to L-CM treated wild-type cells. Data presented as scatter graph illustrating individual data points with an overlay of themean ± SD. (B)HCT116 wild-
type, HCT116 FAM83F−/− (cl.1), DLD-1 wild-type, and DLD-1 FAM83F−/− cells treated with L-CM or Wnt3A-CM for 6 h, were subjected to immunoprecipitation with casein
kinase 1α (CK1α) antibody. Input lysates and CK1α IPs were resolved by SDS–PAGE and subjected to Western blotting with indicated antibodies. (C) Lysates from HCT116
wild-type, HCT116 FAM83F−/− (cl.1), HCT116 FAM83F−/− (cl.2), DLD-1 wild-type, and DLD-1 FAM83F−/− cells following treatment with L-CM or Wnt3A-CM for 4 h, were resolved by
SDS–PAGE and subjected to Western blotting with indicated antibodies. Statistical analysis of (A) was completed using a Student’s unpaired t test and comparing cell
lines as denoted on graph. Statistically significant P-values are denoted by asterisks (**** < 0.0001, *** < 0.001, ** < 0.01, * < 0.05).
Source data are available for this figure.
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Figure 5. FAM83F acts upstream of glycogen synthase kinase-3β and the loss of FAM83F protein reduces casein kinase 1α (CK1α) protein abundance at the plasma
membrane.
(A) qRT-PCR was performed using cDNA from HCT116 wild-type and HCT116 FAM83F−/− (cl.1) cell lines following treatment with L-CM or Wnt3A-CM with or without 0.5 μM
CHIR99021 for 6 h, and primers for Axin2 and GAPDH genes. Axin2 mRNA expression was normalised to GAPDH mRNA expression and represented as arbitrary units. Data
presented as scatter graph illustrating individual data points with an overlay of the mean ± SD. (B) Cytoplasmic, nuclear, and membrane lysates from HCT116 wild-type,
HCT116 FAM83F−/− (cl.1), and HCT116 FAM83F−/− (cl.2) cell lines were resolved by SDS–PAGE and subjected toWestern blotting with indicated antibodies. (C) Densitometry of
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Materials and Methods
Plasmids
All constructs are available for request from the Medical Research
Council-Protein Phosphorylation and Ubiquitylation Unit (MRC-PPU) re-
agents website (http://mrcppureagents.dundee.ac.uk) with the unique
identifier (DU) numbers providing direct links to cloning strategy and
sequence information. Sequences were verified by the DNA sequencing
service, University of Dundee (http://www.dnaseq.co.uk). Constructs
generated include; pcDNA5-FRT/TO GFP only (DU41455), pcDNA5-FRT/TO
GFP FAM83A (DU44235), pcDNA5-FRT/TO GFP FAM83B (DU44236), pcDNA5-
FRT/TO GFP FAM83C (DU42473), pcDNA5-FRT/TO GFP FAM83D (DU42446),
pcDNA5-FRT/TO GFP FAM83E (DU44237), pcDNA5-FRT/TO GFP FAM83F
(DU44238), pcDNA5-FRT/TO GFP FAM83G (DU33272), pcDNA5-FRT/TO
GFP FAM83H (DU44239), pcDNA5-FRT/TO GFP FAM83FC497A (DU28157),
pcDNA5-FRT/TO GFP FAM83FD250A (DU28268), pcDNA5-FRT/TO GFP
FAM83FF284A/F288A (DU28260), pBABED.puro U6 FAM83F tv1 Nter KI
sense (DU54050), pX335 FAM83F Nter KI Antisense (DU54056), pMS-
RQ FAM83F Nter GFP donor (DU54325), pBABED.puro U6 FAM83F ex2
KO sense (DU54848), pX335 FAM83F ex2 KO Antisense (DU54850),
pBABED.puro U6 FAM83F Cter KI Sense A (DU60633), pX335 FAM83F
Cter KI Antisense A (DU60635), and pMA FAM83F Cter C497A internal
ribosome entry site (IRES) GFP donor (DU60711).
To amplify plasmids, 10 μl of Escherichia coli DH5α competent
cells (Invitrogen) were transformed using 1 μl of plasmid DNA. The
bacteria were incubated on ice for 10 min, heat-shocked at 42°C for
45 s, and then incubated in ice for a further 2 min. Transformed
bacteria were spread on ampicillin (100 μg/ml) containing LB-agar
medium plates and incubated at 37°C for 16 h. A 5-ml culture of
ampicillin (100 μg/ml) containing LB medium was inoculated with a
single bacteria colony and incubated at 37°C for 16 h with constant
shaking. Following bacterial growth, the bacteria were pelleted and
plasmid DNA was purified using QIAprep Spin Miniprep Kit (27104;
Quigen) following the manufacturer’s instructions. A NanoDrop
1000 spectrophotometer (Thermo Fisher Scientific) was used to
determine the isolated DNA yield.
Antibodies
Antibodies recognising GFP (S268B), CK1α (SA527), CK1δ (SA609),
CK1ε (SA610), and FAM83F (SA103) are available on request from the
MRC-PPU reagents website (http://mrcppureagents.dundee.ac.uk).
Antibodies for β-actin (#4967), GAPDH (14C10) (#2118), p-LRP6
(S1490) (#2568), LRP6 (C47E12) (#3395), β-catenin (D10A8) (#8480),
phospho-β-catenin (S45) (#9564), phospho-β-catenin (S33/S37/
T41) (#9561), Na/K ATPase (D4Y7E) (#23565), and Lamin A/C
(#2032) were purchased from Cell Signalling Technology. Addi-
tional antibodies used were FAM83G (ab121750; Abcam), α-tubulin
(MA1-80189; Thermo Fisher Scientific), Active-β-catenin (anti-ABC)
clone 8E7 (05-665; END Millipore), mouse anti-GFP clone 7.1 and 13.1
(Roche), mouse-monoclonal anti-HA (H9658; Sigma-Aldrich), and
U2AF1 (PA5-28510; Thermo Fisher Scientific). Secondary antibodies
used were StarBright Blue 700 Goat anti-Rabbit IgG (12004161; Bio-
Rad), StarBright Blue 700 Goat anti-Mouse IgG (12004158; Bio-Rad),
IRDye 800CW Donkey anti-Goat IgG (926-32214; LI-COR), IRDye
800CW Goat anti-Rat IgG (926-32219; LI-COR), IRDye 800CW Goat
anti-Mouse (926-32210; LI-COR), and IRDye 680LT Goat anti-Rabbit
(926-68021; LI-COR).
Constructs and mRNA synthesis for Xenopus assays
Coding sequences for the ORF of fam83fa were obtained from the
Ensembl genome browser (Ensembl release 87—December 2016
EMBL-EBI, GRCz9). Primers were designed to amplify the ORFs to
clone into pENTR/D-TOPO entry vectors (Invitrogen) according to
the manufacturer’s instructions. For fam83fa, the template was
amplified from a previously prepared zebrafish cDNA library. Inserts
were then subcloned into pCS2+ N9HA tagged vectors that had been
converted into Gateway (Invitrogen) destination vectors, according
to the manufacturer’s instructions. Mutant constructs (fam83faF275A,
fam83faF279A, and fam83faF275/279A) were generated by site-directed
mutagenesis using the Q5 Site-Directed Mutagenesis Kit (NEB) accord-
ing to the manufacturer’s instructions. C9 terminal truncation constructs
(fam83fa1-500aa, fam83fa1-400aa, fam83fa1-356aa, and fam83fa1-300aa (DUF))
were generated by pENTR/D-TOPO cloning as previous, using reverse
primers designed accordingly. All constructs were Sanger-sequenced by
the Genomics Equipment Park Science Technology Platform at the Crick.
For mRNA synthesis, PCR templates for in vitro transcription were
generated from the pCS2+ N9 HA–tagged destination vectors. Templates
were thenused in anSP6mMessagemMachine (Invitrogen) transcription
reaction to generate capped mRNAs.
Xenopus laevismaintenance, microinjection and Western blotting
All X. laevis work, including housing and husbandry, was under-
taken in accordance with The Crick Use of Animals in Research
Policy, the Animals (Scientific Procedures) Act 1986 (ASPA) imple-
mented by the Home Office in the UK and the Animal Welfare Act
2006. Consideration was given to the “3Rs” in experimental design.
X. laevis embryos were obtained by in vitro fertilisation and staged
according to Nieuwkoop and Faber (1994) (36). Embryos were
maintained in Normal Amphibian Medium (37) until the four-cell stage
CK1α protein abundance from (B) membrane lysates normalised to GAPDH protein abundance and represented as fold change compared with HCT116 wild-type cells.
Data presented as scatter graph illustrating individual data points with an overlay of the mean ± SD. (D) Cytoplasmic, nuclear, andmembrane lysates from DLD-1 wild-type
and DLD-1 FAM83F−/− cell lines were resolved by SDS–PAGE and subjected toWestern blotting with indicated antibodies. (E) Densitometry of CK1α protein abundance from
(D) membrane lysates normalised to Na/K ATPase protein abundance and represented as fold change compared with DLD-1 wild-type cells. Data presented as scatter
graph illustrating individual data points with an overlay of the mean ± SD. (B, D) The specificity of cytoplasmic, nuclear and membrane compartment lysates were
determined by Western blotting with the following subcellular compartment-specific antibodies: α-tubulin (cytoplasmic), Lamin A/C (nuclear), U2AF1 (nuclear), and Na/K
ATPase (membrane). (A, C, E) Statistical analysis was completed using a Student’s unpaired t test and comparing cell lines as denoted on graphs. Statistically significant
P-values are denoted by asterisks (**** < 0.0001, *** < 0.001, ** < 0.01, * < 0.05).
Source data are available for this figure.
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Figure 6. Membranous localisation of FAM83F is required for FAM83F’s role in canonical Wnt signalling.
(A) Cartoon of the FAM83FC497A knock-in strategy illustrating the genomic DNA sequence in which the C497A point mutation is knocked-in to FAM83F along with an IRES2
(Internal ribosome entry sequence) and GFP coding sequence which are inserted after the FAM83F protein coding sequence and the eventual translated proteins.
(B) Cytoplasmic, nuclear andmembrane lysates fromHCT116 wild-type and HCT116 FAM83FC497A (clones 1–3) cell lines were resolved by SDS–PAGE and subjected toWestern
blotting with indicated antibodies. The specificity of cytoplasmic, nuclear and membrane compartment lysates was determined by Western blotting with the following
subcellular compartment-specific antibodies: α-tubulin (cytoplasmic), Lamin A/C (nuclear), and Na/K ATPase (membrane). (C) Quantification of FAM83F and casein
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was reached, at which point they were injected with 500 pg of the
indicated capped mRNA into a single ventral blastomere. Embryos
were allowed to develop until approximately stage 35 at which point
they were fixed in 4% paraformaldehyde. Embryos were then counted
and scored for secondary axial phenotype classes as shown.
For Western blotting, embryos were obtained as above and injected
into the animal hemisphere at the one-cell stage with 500 pg of the
indicated capped mRNA. Embryos were allowed to develop to stage 10
before being lysed in 10 μl/embryo ice-cold lysis buffer (1% IGEPAL, 150
mM NaCl, 10 mM Hepes, pH 7.4, 2 mM EDTA, and protease inhibitor
cocktail [A32965; Pierce]). Lipids and yolk were removed from the lysate
by FREON extraction (equal volume), and the aqueous phase was
collected following centrifugation for 15min at 4°C. Protein extractswere
then denatured in SDS buffer before being separated by SDS–PAGE (or
snap-frozen on dry ice and stored at −80°C for later). Proteins were then
transferred onto a low-fluorescence polyvinylidene fluoride (LF-PVDF)
(LI-COR) membrane and blocked in Odyssey blocking buffer in TBS (LI-
COR) for 1 h at RT. Blots were then incubated overnight at 4°C in
primary antibodies diluted in Odyssey blocking buffer. Following
TBST washes, blots were then incubated in secondary antibodies
diluted in TBST with 0.02% SDS. Blots were then imaged using the LI-
COR Odyssey imaging system in 700 and 800 nm channels and
processed for brightness and contrast in Adobe Photoshop CC (2019).
Cell culture
U2OS (HTB-96; ATCC), HCT116 (CCL-247; ATCC), DLD-1 (CCL-221; ATCC),
mouse fibroblast L-cells that stably overexpress Wnt3A (CRL-2647;
ATCC), mouse fibroblast L cells (CRL-2648; ATCC), Flp-In T-Rex U2OS
(whichwere created using Flp-In T-Rex Core kit [K650001; Thermo Fisher
Scientific] and have been previously reported (1)), Flp-In T-Rex HEK293
(R78007; Thermo Fisher Scientific) and HaCaT (obtained from Joan
Massague’s lab at Memorial Sloan Kettering Cancer Centre, not com-
mercially available but can be provided on request) (38) cells were
maintained in DMEM (Gibco) containing 10% FCS (Hyclone), 100 U/ml
penicillin (Lonza), 100 mg/ml streptomycin (Lonza), and 2 mM
L-glutamine (Lonza). Cell lines were routinely tested for myco-
plasma contamination and only mycoplasma-free cell lines were
used for experimentation. The additional cell lines reported in Fig
S6 were kindly donated by various research groups within the MRC-
PPU facility (University of Dundee) in the form of cell pellets and
were immediately lysed to determine protein abundance.
Generation of stable Flp-In T-Rex cell lines
The Flp-In T-Rex U2OS were transfected with the N-terminal GFP-
tagged FAM83A, FAM83B, FAM83C, FAM83D, FAM83E, FAM83F, FAM83G,
FAM83H, FAM83FC497A, FAM83FD250A, FAM83FF284A/F288A, or GFP only
packaged in a pcDNA5-FRT/TO vector, along with Flp recombinase
pOG44 (Invitrogen) in a ratio of 1:9 μg. The Flp-In T-Rex HEK293 cells
were transfected with the N-terminal GFP-tagged FAM83F packaged
in a pcDNA5-FRT/TO vector along with Flp recombinase pOG44
(Invitrogen) in a ratio of 1:9 μg. Plasmids were diluted in 1 ml of
OptiMem (Gibco) and 20 μl polyethylenimine (PEI; 1 mg/ml) (Pol-
ysciences) was added. The transfection mixture was vortexed and
incubated for 20 min at room temperature before adding dropwise
to a 10-cm diameter dish of cells in complete culture medium.
Selection of cells was performed 24 h post transfection with the
addition of 50 μg/ml hygromycin and 15 μg/ml blasticidin to
complete culturemedium. Resistant cells were grown to confluency
and tested for expression by Western blotting. Expression was
induced by incubating cells in 20 ng/ml doxycycline for 24 h.
Generation of FAM83F2/2, GFP/GFPFAM83F and FAM83FC497A cell
lines using CRISPR/Cas9
All CRISPR/Cas9 technology procedures were performed using a
dual guide nickase approach. FAM83F knock-out HCT116 (clone.1),
DLD-1, U2OS and HaCaT cell lines were generated by targeting the
FAM83F locus with sense guide RNA (pBabeD-puro vector, DU54848);
GCGTCCAGGATGATGTACACT and antisense guide RNA (pX335-Cas9-
D10A vector, DU54850); GGCAGGAGTGAAGTATTTCC. N-terminal GFP
knock-in to the FAM83F locus in HCT116 and DLD-1 cells were
generated by targeting the FAM83F locus with sense guide RNA
(pBabeD-puro vector, DU54050); GTTCAGCTGGGACTCGGCCA, anti-
sense guide RNA (pX335-Cas9-D10A vector, DU54056); GCGAGGCG-
CACGTGAACGAGA and the GFP-FAM83F donor (pMK-RQ vector,
DU54325). FAM83F−/− HCT116 (clone.2) was generated by the tar-
geting of the N terminus of FAM83F with the intention of knocking in
a GFP tag, but this clone did not incorporate the GFP donor plasmid,
and after inefficient repair of the cut DNA, the clone was null for
FAM83F protein expression. HCT116 FAM83FC497A knock-in cell lines
were generated by targeting the C-terminal of FAM83F with the
sense guide RNA (pBabeD-puro vector, DU60633), antisense guide
RNA (pX335-Cas9-D10A vector, DU60635), and FAM83F C-terminal
donor containing C497A mutation (pMA vector, DU60711). The donor
plasmid contained an IRES and GFP sequence after the FAM83F stop
codon to aid selection of positive clones.
For transfection, plasmids (1 μg of guide RNAs ±3 μg donor) were
diluted in 1 ml OptiMem (Gibco) and 20 μl PEI (1 mg/ml). The
transfection mixture was vortexed for 15 s and incubated for 20 min
at room temperature. This mixture was then added dropwise to a
10-cm diameter dish containing ~70% confluent cells in complete
culture medium. Transfected cells were selected 24 h post-transfection
kinase 1α (CK1α) protein abundance in membrane enriched fractions from (B). FAM83F and CK1α protein abundance is normalised to loading control and presented as
fold-change compared with HCT116 wild-type cells. Data presented as scatter graph illustrating individual data points with an overlay of the mean ± SD. (D) Cell lysates
from HCT116 wild-type, HCT116 FAM83F−/− (cl.1), and HCT116 FAM83FC497A (clones 1–3) cell lines were subjected to immunoprecipitation with anti-CK1α antibody. Input
lysates and CK1α IP elutes were resolved by SDS–PAGE and subjected toWestern blotting with indicated antibodies. (E) qRT-PCR was performed using cDNA from HCT116
wild-type and HCT116 FAM83FC497A (clones 1–4) cell lines following treatment with L-CM or Wnt3A-CM for 6 h, and primers for Axin2 and GAPDH genes. Axin2 mRNA
expression was normalised to GAPDH mRNA expression and represented as fold change compared with L-CM–treated wild-type cells. Data presented as scatter graph
illustrating individual data points with an overlay of themean ± SD. (C, E) Statistical analysis was completed using a Student’s unpaired t test and comparing cell lines as
denoted on graphs. Statistically significant P-values are denoted by asterisks (**** < 0.0001, *** < 0.001, ** < 0.01, * < 0.05).
Source data are available for this figure.
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with the addition of 2 μg/ml puromycin to complete culture
medium for 48 h. Single cells were isolated by FACS with single
GFP-positive cells (for knock-in strategies) or all single cells (for
knock-out strategies) plated in individual wells of a 96-well plate,
pre-coated with 1% (wt/vol) gelatin (Sigma-Aldrich). Viable clones
were expanded and screened by Western blotting for efficient
knock-in or knock-out.
Knock-in and knock-out clones were verified by DNA sequencing.
DNA was isolated from cell pellets using the DNeasy Blood & Tissue
kit (69505; QIAGEN). Primers were generated to amplify the sur-
rounding region of the guide RNA target sites with the following
primer pairs: FAM83F KO exon 2 (forward: TCATTGCTGTGGTCATGGAC,
reverse: AATCCGGAAGTCAGTGAGCT), FAM83F N-terminal GFP KI
(forward: TGCGCGGAAAATGAACTCGTACC, reverse: GTAGAAACCAGTG
TCCGTCCAGC), and FAM83F C-terminal C497A KI (forward: GCTGAATCCA
CCAAGCGTT, reverse: CGTGTGACTGAGATGCTTCG). The region
was amplified by PCR with KOD Hot Start Polymerase (Merck)
according to the manufacturer’s instructions. The PCR products were
visualised on a 1.5% agarose gel using SYBR Safe DNA gel stain
(Invitrogen) and 100-bp and 1-kbp DNA ladders (Promega). The PCR
products of positive clones were then cloned into competent cells
using the StrataClone PCR Cloning Kit (Agilent) according to the
manufacturer’s protocol. Isolation of DNA and sequencing was per-
formed by the MRC-PPU DNA sequencing and services (http://
mrcppureagents.dundee.ac.uk).
Generation of L- and Wnt3A-conditioned medium
Conditioned media were generated from mouse fibroblast L-cells
and mouse fibroblast L-cells that stably overexpress Wnt3A. L-cells
and L-Wnt3A cells were grown in DMEM in 15-cm diameter dishes for
3 d before medium was filtered (0.22 μm) and stored as L-condi-
tioned medium (L-CM) and Wnt3A-conditioned medium (Wnt3A-
CM). Conditioned medium was diluted 50:50 in DMEM containing
10% FCS before use.
Compound treatments
CHIR99021 (Tocris), a highly selective GSK-3 inhibitor, was added to
cells at a concentration of 0.5 μM for 6 h before lysis.
Protein extraction from cells
Cells were washed in PBS twice, scraped in PBS, and pelleted. For
whole-cell protein extractions, cell pellets were resuspended in total
lysis buffer (20 mM Tris–HCl [pH 7.5], 150 mM NaCl, 1 mM Na2EDTA,
1 mM EGTA, 1% [vol/vol] Triton X-100, 2.5 mM sodium pyrophosphate,
1 mM β-glycerophosphate, 1 mM Na3VO4, and 1× complete EDTA-free
protease inhibitor cocktail [Roche]). Lysates were incubated on ice
for 30 min and vortexed regularly then clarified at 17,000g for 20 min.
For cellular fractionation, cell pellets were washed in PBS twice,
scraped in PBS, pelleted, and then separated into cytoplasmic,
nuclear, and membrane lysates using a subcellular protein frac-
tionation kit (Thermo Fisher Scientific) following the manufacturer’s
protocol. Briefly, cell pellets were resuspended in sequential buffers
and clarified to isolate specific cellular compartments (cytoplasmic,
nuclear, membrane, and cytoskeletal).
For cytoplasmic/nuclear protein extractions, cell pellets
resuspended in cytoplasmic lysis buffer (20mM Tris–HCL [pH 7.5], 0.1
mM EDTA, 2 mM MgCl2, 1% NP40, 50 nM β-glycerophosphate, and 1×
complete EDTA-free protease inhibitor cocktail [Roche]) and in-
cubated for 2 min at room temperature, then 10 min on ice, before
clarifying lysate at 1,000g for 5 min. The supernatant was collected
as the cytoplasmic extract before the residual pellet was washed in
wash buffer (20 mM Tris–HCL [pH 7.5], 0.1 mM EDTA, 2 mM MgCl2,
50 nM β-glycerophosphate, and 1× complete EDTA-free protease
inhibitor cocktail [Roche]) three times. The residual pellet was
resuspended in nuclear lysis buffer (20 mM Hepes, 0.4 M NaCl, 25%
glycerol, 1 mM EDTA, 0.5 mM NaF, 0.5 mM Na3VO4, 0.5 mM DTT, and 1×
complete EDTA-free protease inhibitor cocktail [Roche]) and the
pellet disrupted by three quick freeze/thaw cycles then incubated
on ice for 30 min. Lysate was clarified at 17,000g for 20 min at 4°C
with the supernatant collected as the nuclear extract.
Protein extraction from mouse tissue
Mouse tissue samples were obtained from a single male C57BL/6j
mouse, which was obtained from the MRC-PPU after it was des-
ignated as surplus to current breeding requirements and culled by
schedule one methods. Tissue samples were dissected, washed in
PBS and snap frozen in liquid nitrogen. Frozen tissue samples were
ground using a mortar and pestle until the sample was a fine
powder which was then resuspended in PBS and pelleted. This
pellet was resuspended in total lysis buffer (20mM Tris–HCl [pH 7.5],
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% [vol/vol] Triton X-100,
2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM
Na3VO4, and 1× complete EDTA-free protease inhibitor cocktail
[Roche]). Lysates were incubated on ice for 45 min and vortexed
regularly before clarifying at 17,000g for 20 min at 4°C.
For the isolation of single crypts from the mouse small intestine,
a section of proximal small intestine was washed in PBS then cut
into small fragments. Further washing of the fragments in PBS was
completed until minimal contamination remained. The intestinal
fragments were incubated in 3 mM EDTA for 30 min at 4°C on a
rotating wheel to dissociate the crypts. The EDTA was removed and
the fragments gently washed in PBS before washing the fragments
more aggressively in PBS to dislodge the crypts. Crypts were collected
as a component of the supernatant. Crypts were pelleted at 100g for 5
min. The pellet was resuspended in total cell lysis buffer (20 mM
Tris–HCl [pH 7.5], 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% [vol/vol]
Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate,
1 mM Na3VO4, and 1× complete EDTA-free protease inhibitor cocktail
[Roche]). Lysates were incubated on ice for 30 min with regular vor-
texing and clarified at 17,000g for 20 min at 4°C.
SDS–PAGE and Western blotting
The protein concentration of lysates wasmeasured using the Pierce
Coomassie Bradford Protein Assay Kit (Thermo Fisher Scientific).
Final protein concentrations were adjusted to 1–3 μg/μl in lysis
buffer and NuPAGE 4× lithium dodecyl sulphate sample buffer
(NP0007; Thermo Fisher Scientific) was added to a final concen-
tration of 1× and lysates were denatured at 95°C for 5 min. Lysates
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(20–40 μg protein) were separated by SDS–PAGE gels and trans-
ferred to 0.2-μm pore size nitrocellulose membrane (1620112; Bio-
Rad). Following washing in TBS-T (50 mM Tris–HCL [pH 7.5], 150 mM
NaCl, and 0.1% [vol/vol] Tween 20) membranes were incubated in
5% (wt/vol) milk in PBS for 60 min. Membranes were washed in TBS-
T, then incubated in primary antibody (diluted 1:500–1:1,000 in 5%
[vol/vol] milk in TBS-T) for 16 h at 4°C. Membranes were washed in
TBS-T (3 × 10 min), incubated in secondary antibody (diluted 1:5,000
in 5% [vol/vol] milk in TBS-T) for 1 h at room temperature and then
washed in TBS-T (3 × 10 min). Detection of fluorescent secondary
antibody was performed using the Chemidoc system (Bio-Rad) and
Image Lab software (Bio-Rad). Densitometry of protein blots was
completed, using ImageJ software (https://imagej.net), by
measuring the density of protein of interest bands and normal-
ising to that of the corresponding loading control bands. For
subcellular fractions, 15 μg of protein was loaded for each fraction
and the corresponding compartment-specific loading control was
used for densitometry normalisation. Statistical analysis and
preparation of graphs was completed using Microsoft Excel soft-
ware (www.microsoft.com) and Prism 8 (www.graphpad.com),
respectively.
Immunoprecipitation
Lysates were prepared and protein concentrations quantified as de-
scribed previously. For GFP immunoprecipitations (IPs), 10 μl of pre-
equilibrated GFP-Trap Agarose beads (ChromoTek) were added to each
lysate sample (1mgprotein) and incubatedona rotatingwheel for 16 hat
4°C. For antibody-IPs, anti-CK1α (1 μg) antibodywas added to each lysate
sample (1 mg protein), incubated on a rotating wheel for 16 h at 4°C, and
then 20 μl of pre-equilibrated Protein G Sepharose beads (50% beads:
lysis buffer slurry) (DSTT) were added to each lysate sample and incu-
batedona rotatingwheel for 1 hat 4°C. Following incubationof the lysate
with beads, the beads were pelleted, and the supernatant was removed
and stored as flow-through. Beads were washed in lysis buffer three
times before eluting proteins by the addition of 20–40 μl of NuPAGE 1×
lithium dodecyl sulphate sample buffer to the beads and denaturing
proteins by incubating at 95°C for 10 min. The input (IN) and eluted
samples (IP) were separated by SDS–PAGE and subjected to Western
blotting with antibodies as previously outlined.
Immunofluorescence
Cells were plated in 12-well plates containing sterile glass cover-
slips. Cells were incubated for 24 h before removing medium and
incubating cells in 4% paraformaldehyde for 15 min to fix. Following
fixation, cells were permeabilized in 0.2% Triton X-100 for 10 min,
incubated in blocking buffer (5% [wt/vol] bovine serum albumin in
PBS) for 60 min and then washed in TBS-T before incubating in
primary antibody. The following primary antibodies were diluted in
0.5% (wt/vol) bovine serum albumin in TBS-T and incubated for 16 h
at 4°C: mouse anti-GFP (1:1,000) (Roche), sheep anti-CK1α (1:100)
(DSTT), rabbit anti–β-catenin (1:250) (CST) or sheep anti-FAM83F (1:
250) (DSTT). Coverslips were washed in PBS/0.1% Tween-20 (3 × 10
min) then incubated in Alexa Fluor 488 phalloidin, Alexa Fluor
donkey anti-mouse 488 secondary, Alexa Fluor donkey anti-sheep
594 secondary, Alexa Fluor donkey anti-sheep 488 secondary or
Alexa Fluor donkey anti-rabbit 594 secondary (Thermo Fisher
Scientific) diluted (1:500) in 0.5% (wt/vol) bovine serum albumin in
PBS/0.1% Tween-20 for 60 min at room temperature. Coverslips
were washed in PBS/0.1% Tween-20 (3 × 10 min), incubated in 1 μg/
ml DAPI diluted in PBS/0.1% Tween-20 for 5 min at room tem-
perature before further washing in PBS/0.1% Tween-20 (3 × 5 min).
Coverslips were mounted and sealed on glass slides using Vec-
tashield mounting medium (Vector Laboratories) and CoverGrip
coverslip sealant (Biotium), respectively. Fluorescence images were
captured using a Deltavision microscope with a 20×, 60× or 100×
objective. Images were prepared for publication using the Omero
software (www.openmicroscopy.org).
Dual luciferase reporter assays
Cells were plated in six-well plates and grown to ~70% confluence in
complete culture medium. Cells were transfected with either 500 ng of
Super TOPFlash (Addgene) or Super FOPFlash (Addgene) luciferase
plasmids plus 10 ng of Renilla (Addgene) luciferase plasmids. Plasmids
were diluted in 1 ml OptiMem (Gibco) and 20 μl of PEI (1 mg/ml) was
added. The transfection mixture was vortexed then incubated for 20
min at room temperature before adding dropwise to a six-well plate of
cells in complete culture medium. Following transfection (24 h), cells
were treated with either L-conditioned medium or L-Wnt3A-
conditioned medium for 6 h. Cells were washed in PBS twice and
lysed in passive lysis buffer (#E194A; Promega) for 15 min on a rocker.
After lysis, 20 μl of lysate was transferred to triplicate wells in a white
bottom 96-well plate and then 20 μl of 2× luciferase assay buffer (50
mM Tris/Phosphate, 16 mM MgCl2, 2 mM DTT, 1 mM ATP, 30% [vol/vol]
Glycerol, 1% [wt/vol] BSA, 0.25 mM D-luciferin, 8 μM Sodium Pyro-
phosphate) was added to each well, incubated for 2 min, and ab-
sorbance at 560 nmmeasured. Immediately after reading absorbance,
20 μl of 3× Renilla buffer (45 mM Na2EDTA, 30 mM Sodium Pyro-
phosphate, 1.425 MNaCl, 0.06mMPTC124, 0.01mMh-CTZ) was added to
each well and incubated for 5 min before absorbance at 560 nm was
againmeasured. The luciferase absorbance countswere normalised to
Renilla absorbance counts, which represent a measure of transfection
efficiency.
Quantitative real-time PCR (qRT-PCR)
Cells were plated in six-well plates and grown to ~70% confluence in
complete culture medium, then conditioned-medium or treatment
added as indicated. RNA extractions were completed using RNeasy mini
kit (74104; QIAGEN) following the manufacturer’s instructions and RNA
was quantified using a NanoDrop 3300 Fluorospectrometer (Thermo
Fisher Scientific). Synthesis of cDNAwas completedusing 1μg of RNAand
the iScript cDNA synthesis kit (Bio-Rad). Each qRT-PCR was performed as
triplicate reactions with the following reaction mixture: 2 μM forward
primer, 2 μM reverse primer, 50% (vol/vol) iQ SYBR green supermix (Bio-
Rad), and 2 μl cDNA (diluted 1:5) in a 10 μl final volume. Reactions were
completed on a CFX384 real-time system qRT-PCR machine (Bio-Rad).
Primers were designed using Benchling (www.benchling.com) and pur-
chased from Invitrogen.Axin2 forward: TACACTCCTTATTGGGCGATCA,Axin2
reverse: TTGGCTACTCGTAAAGTTTTGGT, GAPDH forward: TGCAC-
CACCAACTGCTTAGC, GAPDH reverse: GGCATGGACTGTGGTCATGAG. The
comparative Ct method (ΔΔCt Method) was used to analyse the
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datasets with Axin2 the Wnt target gene and GAPDH the endogenous
control gene. Statistical analysis and preparation of graphs was com-
pleted using Microsoft Excel software (www.microsoft.com) and Prism 8
(www.graphpad.com), respectively.
Mass spectrometry
Mass spectrometry was performed as previously described (1). Briefly,
expression of GFP-FAM83F in HEK-293 Flp/Trx cells was induced with
doxycycline 24 h before lysis. Cells were lysed and proteins were im-
munoprecipitated using GFP-Trap Agarose beads (ChromoTek) as pre-
viously outlined. Proteins were separated by 4–12% gradient SDS–PAGE,
stained with InstantBlue and gel slices covering each lane were excised
and trypsin-digested. Mass spectrometry analysis of the peptides was
performed by LC-MS/MS on the Linear Ion Trap-Orbitrap Hybris Mass
Spectrometer (Orbitrap Velos Pro; Thermo Fisher Scientific) coupled to a
U3000 RSLC Hplc (Thermo Fisher Scientific). Peptides were trapped on a
nanoViper Trap column and (2 cm × 100 μm, C18, 5 μm, 100 Å; Thermo
Fisher Scientific) and then separated on a 15 cm EASY-spray column
(ES800; Thermo Fisher Scientific) equilibrated with a flow of 300 nl/ml of
3% solvent B (80% acetonitrile, 0.08% formic acis, and 3% DMSO in H2O).
The following elution gradient was completed: time (min)/solvent B (%)
(0:3, 5:3, 45:35, 47:99, 52:99, 55:3, 60:3). Data were acquired in the data-
dependent mode, automatically switching between MS and MS/MS
acquisition. Full-scan spectra (mass/charge ratio [m/z] = 400–1,600)
were acquired in theOrbitrapwith resolution R = 60,000 atm/z 400 (after
accumulation to a Fourier Transform Mass Spectrometry Full Automatic
Gain Control [AGC] Target value of 1,000,000 and an Fourier Transform
Mass Spectrometry Msn AGC Target value of 50,000). The 20most intense
ions, above a specified minimum signal threshold (2,000), based on a
low-resolution (R = 15,000) preview of the survey scan, were fragmented
by collision-induceddissociationand recorded in the linear ion trap (Full
AGC Target, 30,000;MSnAGC Target, 50,000). Data files were analysed
by Proteome Discoverer 2.0 (www.thermoscientific.com), using
Mascot 2.4.1 (www.matrixscience.com) and the SwissProt Human
database. Mascot result files were examined using Scaffold Q/Q+S
V4.4.7 (www.proteomesoftware.com). Allowance was made for the
following fixed (carbamidomethyl [C]) and variable modifications (oxi-
dation [M], deoxidation [M] and Farnesyl [C]). Error tolerances were 10
parts per million for MS1 and 0.6 kD for MS2.
Data Availability
The raw MS proteomics data have been deposited to the Proteo-
meXchange Consortium (http://proteomecentral.proteomexchange.org)
through the PRIDE (PRoteomics IDEntifications) partner repository with
the data set identifier PXD023121. This is an updated analysis to search
for farnesyl (Cys) modification on FAM83F from a previously performed
MS data (PXD009335) (1).
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
202000805.
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